RTP Mobile Logo
Select Publications

Abramson JS et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. ASCO 2018;Abstract 7505.

Alsina M et al. Updated results from the phase I CRB-402 study of anti-Bcma CAR-t cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes. ASH 2020;Abstract 130.

Fowler NH et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: Interim analysis of the phase 2 Elara trial. ASH 2020;Abstract 1149.

Jacobson CA et al. Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2020;Abstract 700.

Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract

Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract

Maloney DG et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). ASH 2020;Abstract 2116.

Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705-16. Abstract

Neelapu SS et al. Chimeric antigen receptor T-cell therapy — Assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47-62. Abstract

Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract

Siddiqi T et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of Transcend CLL 004, including high-risk and ibrutinib-treated patients. ASH 2020;Abstract 546.

van der Steegen SJC et al. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14(7):499-509. Abstract

Wang M et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331-42. Abstract